Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Atorvastatin shown to decrease heart disease and stroke

11.10.2002


Atorvastatin shown to decrease heart disease and stroke in patients with hypertension and low cholesterol



A major European trial studying different blood pressure treatments and the effects of additional cholesterol lowering, announces today that it has stopped part of its trial earlier than expected because results collected already show a significant benefit to patients on one of its treatments.

It found that among 10,297 patients with hypertension and cholesterol levels lower than currently recommended for treatment, those given the cholesterol-lowering drug atorvastatin suffered significantly less heart attacks and strokes compared to those receiving the placebo treatment.


The International Steering Committee of the independent Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) have stopped the relevant part of the trial and informed fellow investigators, their patients and the regulatory authorities about the newly emerged results.

The rest of the trial, which compares different blood pressure treatment strategies, will continue unchanged.

"The trial shows that patients with high blood pressure but low cholesterol benefit clearly from taking a statin. It is too early to quantify the precise size of the effect, but we expect to see a reduction in heart attacks of about one-third among those taking a statin," say ASCOT study co-chairmen Björn Dahlöf from the Sahlgrenska University Hospital, Östra, Sweden and Peter Sever from Imperial College London, UK.

"However the ASCOT trial still continues and we wish to make it clear to all our patients that this new information does not mean they should stop the tablets they are taking. It is vital that all patients on the trial carry on with their treatment regimens," they add.

All patients will be recalled to visit their ASCOT doctors and will be examined again in the coming weeks

Members of ASCOT’s Data Safety Monitoring Board, who work independently of the trial investigators and are the only researchers permitted to look at the results of the five-year old trial while it is ongoing, reported their findings to the ASCOT International Steering Committee on 2 September 2002.

They described a highly significant reduction in the number of heart attacks and a significant reduction in the number of strokes experienced by those patients receiving atorvastatin compared to placebo.

As the size of the benefit exceeded the stopping rules for this part of the trial, the Data Safety Monitoring Board’s recommendations to close this section of the study were accepted by the ASCOT Steering Committee. This part of the study was formally closed on 1 October 2002 but data collection relating to it is expected to continue until the end of December 2002.

Further announcements about the results of the atorvastatin part of the trial will be made in 2003, with final results of the whole ASCOT study expected in 2004.

Patients were only eligible for the cholesterol lowering part of the trial if they had a blood cholesterol level of 6.5 mmol per litre or less - a significantly lower range of cholesterol levels than is usually treated by doctors. This part of the trial is specifically aimed to discover if a statin would confer additional protection against coronary heart disease in hypertensive patients with low cholesterol levels.

The other primary objective of ASCOT is to compare a new treatment strategy for hypertension against an old one, and discover which is better at preventing heart attacks.

The new treatment is a calcium channel blocker (amlodipine), to which in the majority of patients the angiotensin converting enzyme inhibitor, perindopril, is added to achieve the goal blood pressure. The older treatment is a beta blocker (atenolol), to which in the majority of patients a diuretic, bendrofluazide, is added to achieve goal blood pressure.

By May 2000, 19,342 patients had been entered on the trial and randomly selected to receive one of the two blood pressure lowering strategies. Out of the trial total 10,297 patients with low cholesterol were also randomised to receive either placebo or atorvastatin.

Patients in the trial are aged between 40 and 79 years old, with high blood pressure and have at least three other pre-specified cardiovascular risk factors.

The primary endpoint of the trial is either a heart attack from which the patient survives or death from coronary heart disease. A large number of other cardiovascular events including stroke are identified as secondary endpoints in the study.


###

Tony Stephenson | EurekAlert!
Further information:
http://www.ascotstudy.com

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>